



Article

Therapeutic Effectiveness of Interferon- α 2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience

Aleksandr Kamyshnyi ^{1,*}, Halyna Koval ^{2,3}, Olha Kobevko ³, Mykhailo Buchynskiy ¹, Valentyn Oksenysh ⁴, Denis Kainov ⁴, Katerina Lyubomirskaya ⁵, Iryna Kamyshna ⁶, Geert Potters ^{7,8} and Olena Moshynets ^{9,*}

- ¹ Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Majdan Voli 1, 46001 Ternopil, Ukraine
 - ² Department of Clinical Immunology, Allergology and Endocrinology, Bukovinian State Medical University, Teatralnaya Square, 2, 58002 Chernivtsi, Ukraine
 - ³ Department of Infectious Disease, Chernivtsi Regional Clinical Hospital, Holovna, 137, 58000 Chernivtsi, Ukraine
 - ⁴ Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway
 - ⁵ Department of Obstetrics and Gynecology, Zaporizhzhia State Medical University, Maiakovskiy Avenue 26, 69000 Zaporizhzhia, Ukraine
 - ⁶ Department of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, Majdan Voli 1, 46001 Ternopil, Ukraine
 - ⁷ Antwerp Maritime Academy, Noordkasteel Oost 6, 2030 Antwerp, Belgium
 - ⁸ Department of Bioscience Engineering, University of Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium
 - ⁹ Biofilm Study Group, Department of Cell Regulatory Mechanisms, Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, 150 Zabolotnoho Str., 03680 Kyiv, Ukraine
- * Correspondence: kamyshnyi_om@tdmu.edu.ua (A.K.); moshynets@gmail.com (O.M.)



Citation: Kamyshnyi, A.; Koval, H.; Kobevko, O.; Buchynskiy, M.; Oksenysh, V.; Kainov, D.; Lyubomirskaya, K.; Kamyshna, I.; Potters, G.; Moshynets, O. Therapeutic Effectiveness of Interferon- α 2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience. *Int. J. Mol. Sci.* **2023**, *24*, 6887. <https://doi.org/10.3390/ijms24086887>

Academic Editor: Francesco Borgia

Received: 27 February 2023

Revised: 26 March 2023

Accepted: 5 April 2023

Published: 7 April 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Despite several targeted antiviral drugs against SARS-CoV-2 currently being available, the application of type I interferons (IFNs) still deserves attention as an alternative antiviral strategy. This study aimed to assess the therapeutic effectiveness of IFN- α in hospitalized patients with COVID-19-associated pneumonia. The prospective cohort study included 130 adult patients with coronavirus disease (COVID-19). A dose of 80,000 IU of IFN- α 2b was administered daily intranasally for 10 days. Adding IFN- α 2b to standard therapy reduces the length of the hospital stay by 3 days ($p < 0.001$). The level of CT-diagnosed lung injuries was reduced from 35% to 15% ($p = 0.011$) and CT injuries decreased from 50% to 15% ($p = 0.017$) by discharge. In the group of patients receiving IFN- α 2b, the SpO₂ index before and after treatment increased from 94 (92–96, Q₁–Q₃) to 96 (96–98, Q₁–Q₃) ($p < 0.001$), while the percentage of patients with normal saturation increased (from 33.9% to 74.6%, $p < 0.05$), but the level of SpO₂ decreased in the low (from 52.5% to 16.9%) and very low (from 13.6% to 8.5%) categories. The addition of IFN- α 2b to standard therapy has a positive effect on the course of severe COVID-19.

Keywords: IFN- α 2b; COVID-19; therapeutic effectiveness; hospital stay; SpO₂; CT-diagnosed lung injuries

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first appeared in 2019 and caused the coronavirus disease 2019 (COVID-19), which resulted in a global pandemic [1]. This pandemic has triggered severe social and economic distress around the world and the largest global recession since the Great Depression [2,3].

The first COVID-19 cases in Ukraine were registered on 3 March 2020. Within half a year and despite a strict lockdown, four epidemic waves had appeared in Ukraine with approximately 5 million cases confirmed by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (<https://index.minfin.com.ua/reference/coronavirus/ukraine/>, accessed on 24 July 2022).

Since there were initially no specific antiviral drugs or vaccines to control SARS-CoV-2, a wide variety of symptomatic treatment strategies have been proposed, including potential antiviral compounds such as ribavirin [4], lopinavir/ritonavir [5], remdesivir [6], nelfinavir [7], Arbidol [8] and chloroquine [6]. Convalescent plasma and protective monoclonal antibodies were also recommended therapies [9,10].

SARS-CoV-2-specific monoclonal antibodies and convalescent plasma represented another effective treatment strategy to protect at-risk patients, such as immunocompromised and elderly patients, from a severe or lethal course of infection [11]. However, the treatment effectiveness may vary depending on the predominant variant. As it was recently shown, the anti-spike monoclonal antibodies maintained a similar efficacy when the Alpha and Beta variants predominated; however, they showed a reduced effectiveness during the Delta variant epoch [12].

However, even though there are currently several effective vaccines and targeted antiviral drugs against SARS-CoV-2, such as molnupiravir and Paxlovid [13], the application of type I interferons (IFNs) still deserves the attention of virologists as an alternative antiviral strategy.

IFNs are pleotropic cytokines with antiviral activity which have already been reported to be effective in a number of respiratory and non-respiratory viral infections [14–17], as well as against different variants of COVID-19 [18–20]. The announced effectiveness of IFN- α in the treatment of patients with severe COVID-19 has been ambiguous: some work indicated a lack of positive effects [21,22], while at the same time, the effectiveness of such a treatment was confirmed in cohort studies [23,24] as well as clinical trials [25,26]. Our work aimed to assess the clinical effectiveness of IFN- α in hospitalized patients with COVID-19.

2. Results

As presented in Table 1, out of the 130 people who were in the hospital with COVID-19, 81 (62.3%) received IFN- α 2b treatment (Figure 1).




Figure 1. Patient characteristics. Distribution of sex (A) and age (B) within the non-treated (dark grey) and treated (light grey) patient groups.

The addition of IFN- α 2b to the standard therapy reduced the length of hospital stay from 15 to 12 days ($p < 0.001$) (Figure 2A), and reduced CT-diagnosed lung injuries at the time of discharge from 35% to 15% ($p = 0.011$) (Table 2 and Figure 2B). At the same time, compared with the group of patients who did not receive IFN- α 2b, the percentage of CT injuries in treated patients by the end of their hospital stay decreased from 50 to 15% ($p = 0.017$) (Figure 2B).

Table 1. Descriptive statistics for quantitative and categorical variables.

Quantitative Variables	M ± SD/Me	95% CI/Q ₁ –Q ₃	n	min	max
Age, M ± SD	54 ± 14	52–56	130	19	84
Days in hospital, Me	14	12–17	117	7	51
Initial CT% injuries, Me	35	25–45	83	5	91
Final CT% injuries, Me	15	9–36	28	1	75
Initial SpO ₂ , Me	95	93–97	116	81	99
Final SpO ₂ , Me	96	95–98	108	78	99
Categorical Variables	Categories	Abs.	%		
Sex	women	68	52.3		
	men	62	47.7		
IFN-α2b treatment	IFN non-treated	49	37.7		
	IFN treated	81	62.3		
Initial SpO ₂	normal	48	41.4		
	low	56	48.3		
	very low	12	10.3		
Final SpO ₂	normal	78	72.2		
	low	20	18.5		
	very low	10	9.3		

M—mean, Me—margin of error, SD—standard deviation, CI—confidence interval, Q_n—quartile, min—minimum, max—maximum.




Figure 2. Treatment results. Length of hospital stay in control and treatment group (A), and analysis of lung injuries observed by CT (B) before and after the treatment period with (light gray) and without (dark gray) IFN-α2b treatment.

Table 2. Analysis of the level of % CT damage before and after IFN-α2b treatment.

IFN Treatment	Follow-Up Periods				<i>p</i> Initial vs. Final
	%CT Injuries 1 (Initial)		%CT Injuries 2 (Final)		
	Me	Q ₁ –Q ₃	Me	Q ₁ –Q ₃	
IFN-α2b non-treated	25 (<i>n</i> = 7)	22–30	50 (<i>n</i> = 7)	35–60	0.078
IFN-α2b treated	35 (<i>n</i> = 21)	25–45	15 (<i>n</i> = 21)	5–35	0.011 *
<i>p</i> non-treated vs. treated	0.197		0.017 *		–

* Differences are statistically significant (*p* < 0.05).

Initially, the level of SpO₂ in the IFN- α 2b-treated group was lower than in the non-treated group ($p = 0.031$) (Figure 3A); however, upon discharge from the clinic, there was no significant difference between the group which received the treatment and the group which did not ($p = 0.553$) (Figure 3A). However, in the group of patients receiving IFN- α 2b, the SpO₂ index before and after treatment increased from 94 (92–96, Q₁–Q₃) to 96 (96–98, Q₁–Q₃) ($p < 0.001$). The results were more intriguing when we categorized SpO₂ scores into categorical groups (normal saturation—96–100%; low—90–95%; and very low—below 90%) (Figure 3B and Table 3). After IFN- α 2b therapy, the percentage of patients with normal saturation increased (from 33.9% to 74.6, $p < 0.05$), but the level of SpO₂ decreased in the low (from 52.5% to 16.9%) and very low (from 13.6% to 8.5%) categories (Figure 3B and Table 3).




Figure 3. SpO₂ dynamics before and after control (dark gray) and IFN- α 2b treatment (light gray) (A) and SpO₂ relative frequency before and after control and IFN- α 2b treatment (B).

Table 3. Analysis of the level of SpO₂ before and after IFN- α 2b treatment.

IFN- α 2b Treatment	Variables	Follow-Up Periods				<i>p</i> Initial vs. Final
		Initial SpO ₂		Final SpO ₂		
		Abs.	%	Abs.	%	
IFN- α 2b non-treated	normal	23	46.9	34	69.4	0.193
	low	24	49.0	10	20.4	
	very low	2	4.1	5	10.2	
IFN- α 2b treated	normal	20	33.9	44	74.6	<0.001 *
	low	31	52.5	10	16.9	
	very low	8	13.6	5	8.5	
<i>p</i> non-treated vs. treated		0.149		0.836		–

* Differences are statistically significant ($p < 0.05$).

IFN- α 2b treatment significantly increased the level of leukocytes from $4 \times 10^9/L$ to $6 \times 10^9/L$ ($p = 0.028$, Figure 4), but not that of any other blood cell types.

The area under the ROC curve was 0.701 ± 0.084 with a 95% CI: 0.537–0.865 (Figure 4B). The resulting model was statistically significant ($p = 0.031$). The cut-off value of WBCs after IFN- α 2b treatment corresponding to the highest Youden's J statistic was $5.600 \times 10^9/L$. If the WBC value after IFN- α 2b treatment was greater than or equal to this value, IFN- α 2b treatment had a significant effect. The sensitivity and specificity of the method were 52.4% and 77.8%, respectively.




Figure 4. White blood cells (WBCs) following IFN- α 2b treatment (A); ROC curve of WBC elevation prediction following INF treatment (B).

We performed a correlation analysis of the association between quantitative variables using Spearman's correlation coefficient (Table 4 and Figure 5).

Table 4. Results of the correlation analysis.

Variables	Correlation Characteristics		
	ρ	Strength of the Association Assessed Using the Chaddock Scale	p
%CT injuries—Age	0.407	Moderate	0.032 *
%CT injuries—Days in hospital	0.756	Strong	<0.001 *
2SpO2—Days in hospital	−0.544	Close	<0.001 *
%CT injuries—2SpO2	−0.835	Strong	<0.001 *
2SpO2—Age	−0.402	Moderate	<0.001 *

* Differences are statistically significant ($p < 0.05$); 2SpO2—saturation at discharge.

A strong positive association was inferred between the duration of the hospital stay (days in hospital) and the %CT injuries, which could be described by the linear regression equation: $Y_{\text{Days in hospital}} = 0.481 \times X_{\%CT \text{ injuries}} + 3.494$. For a 1% increase in %CT injuries, an increase in the duration of the hospital stay of 0.481 days should be expected. According to the coefficient of determination (R^2) of the resulting model, 72.9% of the observed variance in the number of hospital days was explained.

A close negative association between the number of days in the hospital and the 2SpO2 level was inferred from the linear regression equation: $Y_{\text{Days in hospital}} = -1.518 \times X_{2SpO2} + 160.056$. With a decrease of 1% in the 2SpO2, an increase of 1.518 days in the hospital should be expected. The R^2 of the resulting model indicates that 61.4% of the observed variance in the number of hospital days was explained.

A strong negative association between %CT injuries and 2SpO2 was estimated. The observed dependence of %CT injuries with 2SpO2 is described by the linear regression equation: $Y_{\%CT \text{ injuries}} = -3.476 \times X_{2SpO2} + 354.393$. With a decrease of 1% in the 2SpO2 value, an increase of 3.476 CT injuries should be expected. The R^2 of the resulting model indicates that 79.8% of the observed variance in the %CT injuries was explained.




Figure 5. Regression line characterizing the dependence of days in hospital on %CT injuries, 2SpO2 and age. Statistical significance of correlations when * $p < 0.05$ and *** $p < 0.005$. Grey zones indicate 95% confidence intervals.

Subsequently, a predictive model was developed to estimate the therapeutic effects of IFN- α 2b treatment conditioning on sex, age, days in hospital, % CT injuries and 2SpO2 using binary logistic regression based on 28 observations. The observed relation can be described by the following equations:

$$P = 1/(1 + e^{-z}) \times 100\% \tag{1}$$

$$z = 101.659 + 0.189X_{\text{men}} + 0.006X_{\text{Age}} - 0.246X_{\text{Days in hospital}} - 0.188X_{\% \text{ CT injuries}} - 0.965X_{2\text{SpO}2} \tag{2}$$

where P indicates the probability of the therapeutic effect on a patient treated with IFN- α 2b, X_{men} is the sex of the patient (0—women, 1—men), X_{Age} is the age of the patient, $X_{\text{Days in hospital}}$ is the number of days the patient spent in the hospital, $X_{\% \text{ CT injuries}}$ is the percentage of CT injuries and $X_{2\text{SpO}2}$ is the 2SpO2 value. The resulting regression model is statistically significant ($p = 0.013$). Based on the value of Nagelkerke R^2 , the model explains 59.6% of the observed IFN- α 2b treatment variance (Table 5 and Figure 6A).

Table 5. Characteristics of the association of predictors with the IFN- α 2b treatment.

Predictors	Unadjusted		Adjusted	
	COR; 95% CI	<i>p</i>	AOR; 95% CI	<i>p</i>
Sex: men	1.000; 0.177–5.635	1.000	1.208; 0.054–26.924	0.905
Age	0.993; 0.929–1.061	0.827	1.006; 0.889–1.139	0.923
Days in hospital	0.934; 0.870–1.002	0.057	0.782; 0.534–1.145	0.205
% CT injuries	0.950; 0.908–0.992	0.022 *	0.828; 0.687–0.998	0.047 *
2SpO2	1.083; 0.946–1.241	0.251	0.381; 0.132–1.100	0.074

* Association of the outcome value with the predictor value is statistically significant ($p < 0.05$).




Figure 6. (A) Odds ratios estimate with corresponding 95% CIs for predictors included in the IFN- α 2b treatment model; (B) ROC curve characterizing the dependence of the IFN- α 2b treatment on value of logistic function P and analysis of the sensitivity and specificity of IFN- α 2b treatment depending on the value p of the logistic function.

When evaluating the dependence of the probability of the IFN- α 2b treatment on the value of the logistic function P using the ROC analysis, the curve shown in Figure 6B was obtained. The area under the ROC curve was 0.918 ± 0.052 with a 95% CI: 0.816–1.000. The resulting model was statistically significant ($p = 0.001$). The cut-off value of the logistic function P which corresponded to the highest Youden's J statistic was 0.702. If the logistic function P was greater than or equal to this value, IFN treatment took place. The sensitivity and specificity of the method were 85.7% and 85.7%, respectively (Figure 6B).

3. Discussion

IFN α treatment for COVID-19 has been reported on in more than 180 studies, as we recently analyzed [27]. Among them, there were 64 case reports/series, 54 retrospective/prospective cohort studies, 20 case–control studies, 15 clinical trials, 18 cross-sectional studies, 4 registry studies, 2 longitudinal studies and 1 multinational network cohort study. These studies were conducted in 14 countries (Argentina, Brazil, China, Cuba, France, India, Iran, Malaysia, Qatar, Russia, South Korea, Turkey, the United Arab Emirates (UAE) and the United States of America (USA)). Most of the studies originated in China. There have been no studies conducted in Ukraine but the current one. The given therapeutic forms included solutions or suspensions, and the corresponding routes of administration (ROA) of IFN α treatment in these reports included inhalation or nebulization, subcutaneous injection, intramuscular injection, intravenous injection, a combination of inhalation and injection, injection without a reported site, nasal drops and spray, or the ROA was not reported.

IFN α inhalation later became a part of the standard treatment in China, hence why most studies reporting the use of IFN α inhalation came from China. Other studies using IFN α inhalation included Argentina, Qatar and Russia.

Inhalation/Nebulization or nasal spray was the most commonly reported ROA. The safety of IFN α inhalation was demonstrated in two studies, which reported no difference in the proportion of COVID-19 patients receiving IFN α treatment between those with and without delayed-phase thrombocytopenia, nor between survivors and non-survivors [28,29]. Furthermore, IFN α inhalation seemed to have beneficial effects on the liver during COVID-19 infection. One retrospective cohort study showed an association between IFN α inhalation and lower risks of elevated alanine aminotransferase (>40 U/L) in patients aged between 32 and 56 with ($n = 86$) and without non-alcoholic fatty liver disease ($n = 194$) [30]. These seemingly beneficial impacts of IFN α on the liver are somewhat intriguing, given that liver toxicity is a noted side effect of IFN- α 2. Since IFN- α 2 has been reported to be associated with several autoimmune diseases [31], and due to the absence of any empirical data on IFN- α 2 intranasal application for hospitalized patients with COVID-19-associated pneumonia at the time of the current project, a recommended-by-manufacturer dose of IFN- α 2 (80,000 IU daily) was used. Here, we should also note that the experimental increase in the dosage up to 600,000 IU daily did not show any toxic side effects but improved clinical outcomes with regard to COVID-19 (Moshynets O., personal observations).

Type I IFNs comprise a large family of molecules, including 13 members of the alpha family and 1 member of the beta family, and represent the oldest evolutionary system against viral infections, dating back over 450 million years [32]. Type I IFNs work in both autocrine and paracrine responses, inducing the expression of various interferon-stimulated genes (ISGs) that confer antiviral activity on host cells [33]. Many viral species, including SARS-CoV-2, have evolved various mechanisms to evade the antiviral function of type I IFNs. Up to 10 SARS-CoV-2 proteins have been identified to counteract the antiviral activity of IFNs [34] (Figure 7).




Figure 7. Ways SARS-CoV-2 proteins block interferon signaling.

For instance, the non-structural protein 16 (NSP16) inhibits the splicing of mRNA and reduces the recognition of viral RNA by intracellular helical cases, NSP1 leads to a general inhibition of mRNA translation by binding to 18S ribosomal RNA in the mRNA input canal, and NSP8 and NSP9 disrupt protein traffic through the membrane. These three mechanisms independently result in a reduced production of type I IFNs by the

affected cell [35]. Consequently, any IFN which was synthesized against these barriers and which had exited the cell may not have come in contact with its receptors because they are also partially blocked by ORF3a. Furthermore, any signal that eventually enters the target cell will be blocked at the level of formation of transcription factors IRF3, IRF7 or STAT1. Specifically, ORF6 inhibits STAT1 and STAT2 phosphorylation and STAT1 nuclear translocation, which blocks the transcription of interferon-stimulated genes and the formation of PKR and OAS [36].

A large number of clinical trials of type I IFNs have currently been registered on the clinicaltrials.gov website, in which the compound is being studied either alone (NCT04293887 and NCT04320238) or in combination with other drugs (NCT04254874, NCT04276688, NCT04273763, NCT04315948, NCT04350684 and NCT0435034381). For example, Zhou et al. (2020) [37] showed that treatment with IFN- α 2b—in combination with umifenovir or not—significantly reduced the duration of the virus being detectable in the upper respiratory tract and shortened the duration of the elevated activity of inflammatory markers (IL-6 and CRP). Meng et al. (2020) [38] prospectively evaluated IFN- α 1b nasal drops to prevent the infection of medical staff with SARS-CoV-2 and showed that IFN- α 1b can serve as an effective prophylactic against COVID-19.

While the effects of prophylactic administration of IFNs at an early stage of the disease are obvious, the possibility of using type I IFNs in patients with severe COVID-19 has recently been questioned by some clinicians due to a common misconception about the possibility of an IFN-stimulated increase in inflammation and cytokine storms [39–41]. Despite early reports of suppressed IFN production, there is emerging evidence that patients with severe COVID-19 have a sustained type I IFN response that contrasts with the delayed, possibly suppressed, interferon response seen early on during infection [42]. A sustained type I IFN response may exacerbate hyperinflammation as COVID-19 progresses to a severe disease through a variety of mechanisms. This even led to the launch of a clinical trial on the use of monoclonal antibodies that deplete plasmacytoid dendritic cells, which could potentially lead to a decrease in the production of type I IFNs (<https://clinicaltrials.gov/ct2/show/NCT04526912> (accessed on 14 February 2023)).

The emergence of these misunderstandings was mostly due to prevailing ideas about the purely pro-inflammatory effects of type I IFNs. However, the reality is that these same IFNs can also have immunomodulatory effects, reduce inflammation and cause cytokine storms. Thus, upon infection with the persistence-prone LCMV (lymphocytic choriomeningitis virus), type I IFNs upregulate the expression of programmed death-ligand 1 (PD-L1), and this upregulation leads to the depletion of CD8+ T cells and a decrease in immunopathology [43]. Type I IFNs, released during chronic infections, create an immunosuppressive environment by increasing the expression of PD-L1 and IL-10 via dendritic cells (DCs). These immunoregulatory DCs cause the depletion of CD4+ T cells. Interestingly, the effects of type I IFNs on the functional activity of T-regulatory cells are also ambiguous; however, several studies have shown their ability to enhance the suppressor potential of T-regulatory cells, including by increasing the production of the suppressor cytokine IL-10 [44]. The impact of type I IFN signaling on the activation and differentiation of CD4+ T-cell subpopulations remains poorly defined, and studies report conflicting evidence of a beneficial or detrimental role, depending on the context of the infection [45]. At the same time, interferons can support the expansion of Th1 and Tfh in the acute phase of infection, but cause their depletion during the chronic phase [46]. Type I IFNs can induce antigen-specific T cells to produce IL-10, which in turn, negatively regulates the Th17-mediated inflammatory and autoimmune response [47].

Some concerns regarding IFN therapy might include possible side effects. However, the Solidarity trial did not demonstrate any sign of a cytokine storm following IFN application [48]. In another randomized trial, Davoudi-Monfared et al. (2020) [49] evaluated interferon beta-1a in severe COVID-19 cases. The study group had a higher discharge rate at day 14 (66.7% vs. 43.6%) and a lower mortality rate after 28 days (19% vs. 44%, $p = 0.015$).

A recently published meta-analysis on selected types of immune therapies, including type I IFNs, found significantly lower chances of death (OR, 0.19; 95% CI, 0.04–0.85; $p = 0.03$) for recipients of this type of IFN [50]. A systematic review of the efficacy of IFN- α therapy was carried out by Nakhband et al. (2021) [51] and Lu et al. (2022) [52]. The first group of researchers found that the time of viral clearance and PCR-negative (days) in most studies were decreased in the INF- α + standard care group. The mean length of time until the patient samples became virus negative in the INF- α -treated group and in the standard group were 27.3 and 32.43 days, respectively. Likewise, the average number of days of hospitalization was found to be lower in the INF- α group (18.55 vs. 24.36) [53]. Buchynskyi et al. [27] shows that IFN- α does not increase the survival of hospitalized COVID-19 patients but may increase the number of patients discharged from the hospital.

It should be noted that data on the nature of delayed IFN production are contradictory. Some early studies have shown that SARS-CoV-2 infection induces low levels of type I IFNs and type III IFNs with a moderate ISG response [53]. A more recent study examining peripheral blood from patients with varying degrees of severity of COVID-19 also found that type I IFN responses were severely impaired in patients with severe or critical COVID-19, as indicated by low levels of IFN-I and ISG, despite increased production of tumor necrosis factor (TNF) and IL-6 and increased inflammatory responses controlled by NF- κ B [54]. However, there are conflicting results about increased ISG expression, and in a single-cell RNA sequencing study of peripheral blood mononuclear cells (PBMC) from hospitalized patients with COVID-19, various ISGs were activated in classical monocytes [55]. Interestingly, a comparison of single-cell RNA sequencing in patients with severe COVID-19 and patients with severe influenza showed that patients with COVID-19 had unique hyperinflammatory signatures for all types of immune cells, especially in the upregulation of inflammatory responses caused by TNF and IL-1, whereas type I IFN and type II IFN responses predominated in patients with severe influenza [56]. Type I IFN responses occurred simultaneously with inflammatory responses driven by TNF α and IL-1 β in classical monocytes from patients with severe COVID-19, suggesting that type I IFNs may play an important role in exacerbation.

4. Materials and Methods

4.1. Study Design and Data Collection

The prospective cohort study included 130 adult patients with coronavirus disease (COVID-19) who were treated in the Infectious Diseases Department of the Chernivtsi Regional Clinical Hospital from November 2020 to May 2021. All patients were hospitalized for clinical indications of SARS-CoV-2 infection, which was confirmed by laboratory RT-PCR testing of a nasopharyngeal swab. Patients had been showing symptoms up to 7 days before hospitalization.

4.2. Clinical Characteristics of the Patients

As presented in Table 1 and Figure 1, the project included 130 patients with community-acquired COVID-19 pneumonia, which was confirmed by computed tomography (CT) of the chest. All patients underwent a diagnostic examination as well as monitoring in accordance with national recommendations. The patients had neither been vaccinated nor had COVID-19 disease before. The inclusion criteria were: (1) Patients diagnosed with COVID-19 by laboratory confirmation of SARS-CoV-2 via reverse transcriptase-polymerase chain reaction assays of the throat, which were assessed via swabs. (2) Severe or moderate COVID-19 infection meeting at least one of the following: (a) respiratory distress, defined as a respiratory rate ≥ 30 times/min (severe COVID-19) or ≥ 22 times/min (moderate COVID-19); (b) oxygen saturation $\leq 90\%$ at rest (severe COVID-19), or in the range of 91–95% (moderate COVID-19); and (c) the symptoms showed progressive aggravation, and a chest X-ray or CT indicated that the lesions had progressed more than 50% within 24–48 h. (3) Patients with clear clinical outcomes (discharged). (4) Patients with community-acquired COVID-19 pneumonia, which was confirmed by computed tomography (CT)

of the chest. The exclusion criteria were: (1) patients with incomplete medical records (e.g., transfer to other hospitals); (2) patients who were intubated, dead or discharged within 24 h of admission; (3) patients that were pregnant or had acute lethal organ injury (e.g., acute myocardial infarction, acute pulmonary embolism or acute stroke), acquired immune deficiency syndrome or leukemia; and (4) patients younger than 18 years. These specific criteria were established to avoid the non-uniform enrolment of patients, which could skew the interpretation of the results.

Moderate COVID-19 was defined by the following symptoms: fever above 38 °C; respiratory rate more than 22/min; shortness of breath during exercise; pneumonia (CT infiltrates in the lungs <45% of the pulmonary area); and SpO₂ > 90%.

Severe COVID-19 was defined by the following symptoms: respiratory rate greater than 30/min; oxygen saturation (SpO₂) ≤ 90%; the ratio of arterial oxygen partial pressure (PaO₂ in mmHg) to fractional inspired oxygen, or PaO₂/FiO₂, ≤ 300 mm Hg; and progression of changes in the lungs typical of COVID-19 pneumonia (CT infiltrates in the lungs > 45–50% of the pulmonary area).

All patients were under standard treatment according to the national treatment protocol for COVID-19, which included: symptomatic antipyretic therapy (paracetamol or ibuprofen); anticoagulant therapy (low-molecular-weight heparins such as enoxaparin at a dose of 40 mg (4000 IU anti-Xa)); antimicrobial treatment of co-infections (amoxicillin/clavulanate plus macrolides (azithromycin or clarithromycin) or cephalosporins of the II–III generation plus macrolides (azithromycin or clarithromycin)); corticosteroids (0.15 mg/kg IV of dexamethasone once a day (maximum dose 6 mg) for 7–10 days); and non-invasive oxygen support. The duration of a hospital stay ranged from 7 to 51 days.

4.3. Randomization, IFN- α Treatment and Outcomes

The selected patients were randomly divided into treatment and control groups by simple open randomization. The treatment group consisted of 81 patients (62.3%). The control group included 49 patients (37.7%). The groups did not substantially differ in comorbidities. The treatment group of patients received nasal interferon alpha-2b (IFN- α 2b) in addition to the standard therapy (described above).

Starting the first day of hospitalization, IFN- α 2b was administered in the form of a nasal spray through 2 spray-doses into each nasal passage 4 times a day using 5 mL vials of Nasoferon (JSC "Farmak", Kyiv, Ukraine) that consisted of 100,000 IU per ml and 5000 IU per spray-dose, which was a total of 80,000 IU per day for 10 days. The study protocol met the requirements for biomedical research and was approved by the Local Ethics Committee of the Chernivtsi Regional Clinical Hospital as protocol N10, dated 3 October 2020.

The primary outcome was the length of the hospital stay. The secondary outcomes included the level of CT-diagnosed lung injuries at the time of discharge and the after-before dynamics of SpO₂ level due to IFN- α 2b treatment.

4.4. Statistical Analysis

Continuous variables were described as median values (interquartile ranges (IQRs)) and compared with a Mann–Whitney test. Categorical variables were described as frequencies (percentages) and compared with a chi-squared test or Fisher's exact test where appropriate. All inter-group comparisons were between the IFN- α 2b group and the control group. The development of a prognostic model for the probability of a binary outcome was carried out using logistic regression. The Nagelkerke R² was used as a measure of model performance.

Receiver operating characteristic (ROC) analysis was used to assess the diagnostic performance of quantitative variables in predicting a categorical outcome. The optimal cut-off value of the quantitative variable was estimated using Youden's J statistic. A two-sided α of less than 0.05 was considered statistically significant.

5. Conclusions

1. Adding IFN- α 2b to the standard therapy for patients with severe COVID-19 reduces the length of the hospital stay by 3 days ($p < 0.001$).
2. Treatment with IFN- α 2b reduces the level of CT-diagnosed lung injuries from 35% to 15% ($p = 0.011$) at the time of discharge and, compared with the group of patients who did not receive IFN- α 2b, the percentage of CT injuries decreases at the end of the hospital stay from 50 to 15% ($p = 0.017$).
3. In the group of patients receiving IFN- α 2b, the SpO₂ index before and after treatment increased from 94 (92–96, Q₁–Q₃) to 96 (96–98, Q₁–Q₃) ($p < 0.001$), while the percentage of patients with normal saturation increased (from 33.9% to 74.6, $p < 0.05$), but the level of SpO₂ decreased in the low (from 52.5% to 16.9%) and very low (from 13.6% to 8.5%) categories.
4. Considering the contradictory results obtained regarding the strength of the response to type I IFNs in patients with severe COVID-19, more accurate information is required for the appropriate therapeutic use of type I IFNs.

Author Contributions: Conceptualization, A.K., H.K. and O.M.; data curation, A.K. and H.K.; formal analysis, A.K., V.O. and D.K.; investigation, H.K. and O.K.; methodology, H.K.; project administration, A.K. and H.K.; resources, H.K., O.K. and G.P.; supervision, A.K.; validation, A.K., K.L. and I.K.; visualization, A.K.; writing—original draft, A.K., M.B., G.P. and O.M.; writing—review and editing, A.K., G.P. and O.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study protocol met the requirements for biomedical research and was approved by the Local Ethics Committee of the Chernivtsi Regional Clinical Hospital as protocol N10, dated 3 October 2020.

Informed Consent Statement: All patients signed an informed consent for the study.

Data Availability Statement: All the raw data can be provided by the authors upon request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. WHO Director-General's Opening Remarks at the Media Briefing on COVID-19—11 March 2020. Available online: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020> (accessed on 15 February 2023).
2. Aktar, M.A.; Alam, M.M.; Al-Amin, A.Q. Global Economic Crisis, energy use, CO₂ emissions, and policy roadmap amid COVID-19. *Sustain. Prod. Consum.* **2021**, *26*, 770–781. [CrossRef]
3. Jaroń, A.; Borucka, A.; Parczewski, R. Analysis of the impact of the COVID-19 pandemic on the value of CO₂ emissions from electricity generation. *Energies* **2022**, *15*, 4514. [CrossRef]
4. Morgenstern, B.; Michaelis, M.; Baer, P.C.; Doerr, H.W.; Cinatl, J.J. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. *Biochem. Biophys. Res. Commun.* **2005**, *326*, 905–908. [CrossRef]
5. Chu, C.M.; Cheng, V.C.C.; Hung, I.F.N.; Wong, M.M.L.; Chan, K.H.; Chan, K.S.; Kao, R.Y.T.; Poon, L.L.M.; Wong, C.L.P.; Guan, Y.; et al. Role of Lopinavir/Ritonavir in the treatment of SARS: Initial virological and clinical findings. *Thorax* **2004**, *59*, 252–256. [CrossRef] [PubMed]
6. Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and Chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in Vitro. *Cell Res.* **2020**, *30*, 269–271. [CrossRef]
7. Yamamoto, N.; Yang, R.; Yoshinaka, Y.; Amari, S.; Nakano, T.; Cinatl, J.; Rabenau, H.; Doerr, H.W.; Hunsmann, G.; Otaka, A.; et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. *Biochem. Biophys. Res. Commun.* **2004**, *318*, 719–725. [CrossRef] [PubMed]
8. Zhu, Z.; Lu, Z.; Xu, T.; Chen, C.; Yang, G.; Zha, T.; Lu, J.; Xue, Y. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. *J. Infect.* **2020**, *81*, e21–e23. [CrossRef]
9. Li, H.; Wang, Y.M.; Xu, J.Y.; Cao, B. Potential antiviral therapeutics for 2019 Novel Coronavirus. *Zhonghua Jie He He Hu Xi Za Zhi Zhonghua Jie He He Huxi Zazhi Chin. J. Tuberc. Respir. Dis.* **2020**, *43*, E002. [CrossRef]
10. Li, D.; Sempowski, G.D.; Saunders, K.O.; Acharya, P.; Haynes, B.F. SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment. *Annu. Rev. Med.* **2022**, *73*, 1–16. [CrossRef]

11. Thümmler, L.; Lindemann, M.; Horn, P.A.; Lenz, V.; Konik, M.; Gäckler, A.; Boss, K.; Theodoropoulos, F.; Besa, V.; Taube, C.; et al. Early treatment with monoclonal antibodies or convalescent plasma reduces mortality in non-vaccinated COVID-19 high-risk patients. *Viruses* **2023**, *15*, 119. [[CrossRef](#)]
12. O'Horo, J.C.; Challener, D.W.; Speicher, L.; Bosch, W.; Seville, M.T.; Bierle, D.M.; Ganesh, R.; Wilker, C.G.; Arndt, R.F.; Arndt, L.L.; et al. Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of the delta variant. *Mayo Clin. Proc.* **2022**, *97*, 327–332. [[CrossRef](#)]
13. Wen, W.; Chen, C.; Tang, J.; Wang, C.; Zhou, M.; Cheng, Y.; Zhou, X.; Wu, Q.; Zhang, X.; Feng, Z.; et al. Efficacy and safety of three new oral antiviral treatment (Molnupiravir, Fluvoxamine and Paxlovid) for COVID-19: A Meta-Analysis. *Ann. Med.* **2022**, *54*, 516–523. [[CrossRef](#)]
14. Jaeckel, E.; Cornberg, M.; Wedemeyer, H.; Santantonio, T.; Mayer, J.; Zankel, M.; Pastore, G.; Dietrich, M.; Trautwein, C.; Manns, M.P. Treatment of acute hepatitis C with interferon Alfa-2b. *N. Engl. J. Med.* **2001**, *345*, 1452–1457. [[CrossRef](#)]
15. Feld, J.J.; Hoofnagle, J.H. mechanism of action of interferon and Ribavirin in treatment of hepatitis C. *Nature* **2005**, *436*, 967–972. [[CrossRef](#)]
16. Falzarano, D.; de Wit, E.; Rasmussen, A.L.; Feldmann, F.; Okumura, A.; Scott, D.P.; Brining, D.; Bushmaker, T.; Martellaro, C.; Baseler, L.; et al. Treatment with interferon- α 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. *Nat. Med.* **2013**, *19*, 1313–1317. [[CrossRef](#)]
17. Hijano, D.R.; Vu, L.D.; Kauvar, L.M.; Tripp, R.A.; Polack, F.P.; Cormier, S.A. Role of type I interferon (IFN) in the respiratory syncytial virus (RSV) immune response and disease severity. *Front. Immunol.* **2019**, *10*, 566. [[CrossRef](#)]
18. Guo, K.; Barrett, B.S.; Morrison, J.H.; Mickens, K.L.; Vladar, E.K.; Hasenkrug, K.J.; Poeschla, E.M.; Santiago, M.L. Interferon resistance of emerging SARS-CoV-2 variants. *Proc. Natl. Acad. Sci. USA* **2022**, *119*, e2203760119. [[CrossRef](#)]
19. Ianevski, A.; Yao, R.; Zusinaite, E.; Lello, L.S.; Wang, S.; Jo, E.; Yang, J.; Ravlo, E.; Wang, W.; Lysvand, H.; et al. Synergistic interferon-Alpha-Based combinations for treatment of SARS-CoV-2 and other viral infections. *Viruses* **2021**, *13*, 2489. [[CrossRef](#)]
20. Ianevski, A.; Yao, R.; Lysvand, H.; Grødeland, G.; Legrand, N.; Oksenysh, V.; Zusinaite, E.; Tenson, T.; Bjørås, M.; Kainov, D.E. Nafamostat-interferon- α combination suppresses SARS-CoV-2 infection in vitro and in vivo by cooperatively targeting host TMPRSS2. *Viruses* **2021**, *13*, 1768. [[CrossRef](#)]
21. Gong, W.J.; Zhou, T.; Wu, S.-L.; Ye, J.-L.; Xu, J.-Q.; Zeng, F.; Su, Y.-Y.; Han, Y.; Lv, Y.-N.; Zhang, Y.; et al. A retrospective analysis of clinical efficacy of Ribavirin in adults hospitalized with severe COVID-19. *J. Infect. Chemother. Off. J. Japan Soc. Chemother.* **2021**, *27*, 876–881. [[CrossRef](#)]
22. Li, X.; Zhou, L.; Zhang, L.; Zheng, S.; Huang, F.; Pan, X.; Wang, F. The combined regimens of antiviral therapy might not be useful for the viral clearance of severe COVID-19 cases. *J. Infect. Public Health* **2021**, *14*, 1693–1700. [[CrossRef](#)]
23. Zhou, Q.; MacArthur, M.R.; He, X.; Wei, X.; Zarin, P.; Hanna, B.S.; Wang, Z.-H.; Xiang, X.; Fish, E.N. Interferon- α 2b treatment for COVID-19 is associated with improvements in lung abnormalities. *Viruses* **2020**, *13*, 44. [[CrossRef](#)] [[PubMed](#)]
24. Yin, P.; Meng, J.; Chen, J.; Gao, J.; Wang, D.; Liu, S.; Guo, Q.; Zhu, M.; Zhang, G.; Liu, Y.; et al. Antiviral drugs Arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: A retrospective cohort study. *Virol. J.* **2021**, *18*, 142. [[CrossRef](#)] [[PubMed](#)]
25. Pandit, A.; Bhalani, N.; Bhushan, B.L.S.; Koradia, P.; Gargiya, S.; Bhomia, V.; Kansagra, K. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study. *Int. J. Infect. Dis.* **2021**, *105*, 516–521. [[CrossRef](#)]
26. Bhushan, B.L.; Wanve, S.; Koradia, P.; Bhomia, V.; Soni, P.; Chakraborty, S.; Khobragade, A.; Joshi, S.; Mendiratta, S.K.; Kansagra, K.K.; et al. Efficacy and safety of pegylated interferon- α 2b in moderate COVID-19: A phase 3, randomized, comparator-controlled, open-label study. *Int. J. Infect. Dis.* **2021**, *111*, 281–287. [[CrossRef](#)]
27. Buchynskiy, M.; Kamyshna, I.; Lyubomirskaya, K.; Moshynets, O.; Kobylak, N.; Oksenysh, V.; Kamyshnyi, A. efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis. *Front. Immunol.* **2023**, *14*, 250. [[CrossRef](#)] [[PubMed](#)]
28. Chen, F.; Zhong, M.; Liu, Y.; Zhang, Y.; Zhang, K.; Su, D.; Meng, X.; Zhang, Y. The characteristics and outcomes of 681 severe cases with COVID-19 in China. *J. Crit. Care* **2020**, *60*, 32–37. [[CrossRef](#)] [[PubMed](#)]
29. Chen, W.; Li, Z.; Yang, B.; Wang, P.; Zhou, Q.; Zhang, Z.; Zhu, J.; Chen, X.; Yang, P.; Zhou, H. Delayed-phase thrombocytopenia in patients with coronavirus disease 2019 (COVID-19). *Br. J. Haematol.* **2020**, *190*, 179–184. [[CrossRef](#)]
30. Huang, R.; Zhu, L.; Wang, J.; Xue, L.; Liu, L.; Yan, X.; Huang, S.; Li, Y.; Yan, X.; Zhang, B.; et al. Clinical features of patients with COVID-19 with nonalcoholic fatty liver disease. *Hepatol. Commun.* **2020**, *4*, 1758–1768. [[CrossRef](#)]
31. Lombardi, A.; Tsomos, E.; Hammerstad, S.S.; Tomer, Y. Interferon alpha: The key trigger of type 1 diabetes. *J. Autoimmun.* **2018**, *94*, 7–15. [[CrossRef](#)]
32. Park, A.; Iwasaki, A. Type I and type III interferons-induction, signaling, evasion, and application to combat COVID-19. *Cell Host Microbe* **2020**, *27*, 870–878. [[CrossRef](#)] [[PubMed](#)]
33. Schoggins, J.W. Interferon-stimulated genes: What Do They All Do? *Annu. Rev. Virol.* **2019**, *6*, 567–584. [[CrossRef](#)] [[PubMed](#)]
34. Mantlo, E.; Bukreyeva, N.; Maruyama, J.; Paessler, S.; Huang, C. Antiviral activities of type I interferons to SARS-CoV-2 infection. *Antivir. Res.* **2020**, *179*, 104811. [[CrossRef](#)] [[PubMed](#)]
35. Fisher, T.; Gluck, A.; Narayanan, K.; Kuroda, M.; Nachshon, A.; Hsu, J.C.; Halfmann, P.J.; Yahalom-Ronen, Y.; Tamir, H.; Finkel, Y.; et al. Parsing the role of NSP1 in SARS-CoV-2 infection. *Cell Rep.* **2022**, *39*, 110954. [[CrossRef](#)]

36. Glanz, A.; Chakravarty, S.; Varghese, M.; Kottapalli, A.; Fan, S.; Chakravarti, R.; Chattopadhyay, S. Transcriptional and non-transcriptional activation, posttranslational modifications, and antiviral functions of interferon regulatory factor 3 and viral antagonism by the SARS-coronavirus. *Viruses* **2021**, *29*, 575. [[CrossRef](#)]
37. Zhou, Q.; Chen, V.; Shannon, C.P.; Wei, X.-S.; Xiang, X.; Wang, X.; Wang, Z.-H.; Tebbutt, S.J.; Kollmann, T.R.; Fish, E.N. Interferon- α 2b treatment for COVID-19. *Front. Immunol.* **2020**, *11*, 1061. [[CrossRef](#)]
38. Meng, Z.; Wang, T.; Chen, L.; Chen, X.; Li, L.; Qin, X.; Li, H.; Luo, J. The effect of recombinant human interferon alpha nasal drops to prevent COVID-19 pneumonia for medical staff in an epidemic area. *Curr. Top. Med. Chem.* **2021**, *21*, 920–927. [[CrossRef](#)]
39. Pereda, R.; González, D.; Rivero, H.B.; Rivero, J.C.; Pérez, A.; Lopez, L.D.R.; Mezquia, N.; Venegas, R.; Betancourt, J.R.; Domínguez, R.E.; et al. Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery. *J. Interf. Cytokine Res.* **2020**, *40*, 578–588. [[CrossRef](#)]
40. Wang, N.; Zhan, Y.; Zhu, L.; Hou, Z.; Liu, F.; Song, P.; Qiu, F.; Wang, X.; Zou, X.; Wan, D.; et al. retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. *Cell Host Microbe* **2020**, *28*, 455–464.e2. [[CrossRef](#)]
41. Zhou, Z.; Ren, L.; Zhang, L.; Zhong, J.; Xiao, Y.; Jia, Z.; Guo, L.; Yang, J.; Wang, C.; Jiang, S.; et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. *Cell Host Microbe* **2020**, *27*, 883–890.e2. [[CrossRef](#)]
42. Lopez, L.; Sang, P.C.; Tian, Y.; Sang, Y. dysregulated interferon response underlying severe COVID-19. *Viruses* **2020**, *12*, 1433. [[CrossRef](#)]
43. Shaabani, N.; Duhan, V.; Khairnar, V.; Gassa, A.; Ferrer-Tur, R.; Häussinger, D.; Recher, M.; Zelinsky, G.; Liu, J.; Dittmer, U.; et al. CD169(+) macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection. *Cell Death Dis.* **2016**, *7*, e2446. [[CrossRef](#)]
44. Piconese, S.; Pacella, I.; Timperi, E.; Barnaba, V. Divergent Effects of Type-I Interferons on Regulatory T Cells. *Cytokine Growth Factor Rev.* **2015**, *26*, 133–141. [[CrossRef](#)]
45. Kuka, M.; De Giovanni, M.; Iannaccone, M. The role of type I interferons in CD4+ T cell differentiation. *Immunol. Lett.* **2019**, *215*, 19–23. [[CrossRef](#)]
46. Wilson, E.B.; Yamada, D.H.; Elsaesser, H.; Herskovitz, J.; Deng, J.; Cheng, G.; Aronow, B.J.; Karp, C.L.; Brooks, D.G. Blockade of chronic type I interferon signaling to control persistent LCMV infection. *Science* **2013**, *340*, 202–207. [[CrossRef](#)]
47. Zhang, L.; Yuan, S.; Cheng, G.; Guo, B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. *PLoS ONE* **2011**, *6*, e28432. [[CrossRef](#)]
48. Pan, H.; Peto, R.; Henao-Restrepo, A.-M.; Preziosi, M.-P.; Sathiyamoorthy, V.; Abdool Karim, Q.; Alejandria, M.M.; Hernández García, C.; Kieny, M.-P.; Malekzadeh, R.; et al. Repurposed antiviral drugs for COVID-19—Interim WHO Solidarity Trial Results. *N. Engl. J. Med.* **2021**, *384*, 497–511. [[CrossRef](#)]
49. Davoudi-Monfared, E.; Rahmani, H.; Khalili, H.; Hajiabdolbaghi, M.; Salehi, M.; Abbasian, L.; Kazemzadeh, H.; Yekaninejad, M.S. A randomized clinical trial of the efficacy and safety of interferon β -1a in treatment of severe COVID-19. *Antimicrob. Agents Chemother.* **2020**, *64*, e01061-20. [[CrossRef](#)]
50. Walz, L.; Cohen, A.J.; Rebaza, A.P.; Vanchieri, J.; Slade, M.D.; Dela Cruz, C.S.; Sharma, L. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: A systematic review and meta-analysis. *Res. Sq.* **2020**, *21*, 47. [[CrossRef](#)]
51. Nakhband, A.; Fakhari, A.; Azizi, H. interferon-alpha position in combating with COVID-19: A systematic review. *J. Med. Virol.* **2021**, *93*, 5277–5284. [[CrossRef](#)]
52. Lu, L.-Y.; Feng, P.-H.; Yu, M.-S.; Chen, M.-C.; Lin, A.J.-H.; Chen, J.L.; Yu, L.H.-L. current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review. *Cytokine Growth Factor Rev.* **2022**, *63*, 34–43. [[CrossRef](#)] [[PubMed](#)]
53. Blanco-Melo, D.; Nilsson-Payant, B.E.; Liu, W.-C.; Uhl, S.; Hoagland, D.; Möller, R.; Jordan, T.X.; Oishi, K.; Panis, M.; Sachs, D.; et al. imbalanced host response to SARS-CoV-2 drives development of COVID-19. *Cell* **2020**, *181*, 1036–1045.e9. [[CrossRef](#)] [[PubMed](#)]
54. Hadjadj, J.; Yatim, N.; Barnabei, L.; Corneau, A.; Boussier, J.; Smith, N.; Péré, H.; Charbit, B.; Bondet, V.; Chenevier-Gobeaux, C.; et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* **2020**, *369*, 718–724. [[CrossRef](#)] [[PubMed](#)]
55. Wilk, A.J.; Rustagi, A.; Zhao, N.Q.; Roque, J.; Martinez-Colon, G.J.; McKechnie, J.L.; Ivison, G.T.; Ranganath, T.; Vergara, R.; Hollis, T.; et al. A single-cell atlas of the peripheral immune response to severe COVID-19. *Nat. Med.* **2020**, *26*, 1070–1076. [[CrossRef](#)] [[PubMed](#)]
56. Lee, J.S.; Park, S.; Jeong, H.W.; Ahn, J.Y.; Choi, S.J.; Lee, H.; Choi, B.; Nam, S.K.; Sa, M.; Kwon, J.S.; et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. *Sci. Immunol.* **2020**, *5*, 1554. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.